Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs)—both ‘short’ and ‘long’ acting—induce moderate weight loss in obese subjects with or without type 2 diabetes (T2D) [1,2,3,4,5]. This evidence concerns the gene GCG and type 2 diabetes mellitus.